Trials / Unknown
UnknownNCT05742230
Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)
Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure: a Multicenter, Prospective, Pragmatic Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,932 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the superiority of the effectiveness of Henagliflozin 10 milligram (mg) daily versus blank control in participants with type II diabetes (T2DM) and symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Henagliflozin 10 mg | Participants will receive 10 mg single oral tablets orally once daily. |
| DRUG | blank control | standard treatment |
Timeline
- Start date
- 2023-04-15
- Primary completion
- 2024-07-31
- Completion
- 2025-12-31
- First posted
- 2023-02-23
- Last updated
- 2023-02-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05742230. Inclusion in this directory is not an endorsement.